Latest Insider Transactions at Veracyte, Inc. (VCYT)
This section provides a real-time view of insider transactions for Veracyte, Inc. (VCYT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERACYTE, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERACYTE, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
14,731
-16.56%
|
$545,047
$37.77 P/Share
|
|
Nov 12
2024
|
Robert S Epstein Director |
SELL
Open market or private sale
|
Direct |
15,000
-25.17%
|
$570,000
$38.32 P/Share
|
|
Nov 12
2024
|
Robert S Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+20.11%
|
$120,000
$8.04 P/Share
|
|
Nov 12
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,275
-10.93%
|
$580,450
$38.34 P/Share
|
|
Sep 19
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
5,173
-100.0%
|
$181,055
$35.23 P/Share
|
|
Sep 04
2024
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
5,479
-6.71%
|
$158,891
$29.78 P/Share
|
|
Sep 03
2024
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,507
+50.0%
|
-
|
|
Sep 03
2024
|
Thomas F. Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,507
+50.0%
|
-
|
|
Sep 02
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,464
-2.42%
|
$107,384
$31.55 P/Share
|
|
Sep 02
2024
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,920
-2.01%
|
$59,520
$31.55 P/Share
|
|
Sep 02
2024
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,087
-2.24%
|
$33,697
$31.55 P/Share
|
|
Sep 02
2024
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,748
-1.77%
|
$178,188
$31.55 P/Share
|
|
Sep 02
2024
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,315
-1.58%
|
$40,765
$31.55 P/Share
|
|
Aug 13
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
27,188
-35.2%
|
$870,016
$32.1 P/Share
|
|
Aug 13
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
20,457
-13.26%
|
$654,624
$32.11 P/Share
|
|
Aug 13
2024
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,486
+13.41%
|
$84,860
$10.41 P/Share
|
|
Aug 12
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
101
-0.31%
|
$3,030
$30.0 P/Share
|
|
Aug 12
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
99
-0.21%
|
$2,970
$30.01 P/Share
|
|
Aug 09
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
746
-2.25%
|
$22,380
$30.03 P/Share
|
|
Aug 09
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
1,032
-2.18%
|
$30,960
$30.03 P/Share
|
|
Aug 09
2024
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.63%
|
$3,000
$10.41 P/Share
|
|
Aug 07
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
5,108
-10.16%
|
$153,240
$30.32 P/Share
|
|
Aug 07
2024
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,214
+2.36%
|
$12,140
$10.41 P/Share
|
|
Aug 07
2024
|
Jens Holstein Director |
SELL
Open market or private sale
|
Direct |
5,000
-7.92%
|
$145,000
$29.0 P/Share
|
|
Jul 16
2024
|
Jens Holstein Director |
SELL
Open market or private sale
|
Direct |
5,000
-6.83%
|
$120,000
$24.5 P/Share
|
|
Jul 16
2024
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
1,277
-1.52%
|
$31,925
$25.0 P/Share
|
|
Jul 16
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
7,500
-18.41%
|
$187,500
$25.0 P/Share
|
|
Jun 13
2024
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,473
+21.98%
|
-
|
|
Jun 13
2024
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,473
+20.46%
|
-
|
|
Jun 13
2024
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,473
+24.91%
|
-
|
|
Jun 13
2024
|
Jens Holstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,473
+23.25%
|
-
|
|
Jun 13
2024
|
Eliav Barr Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,473
+21.51%
|
-
|
|
Jun 13
2024
|
Evan/ Fa Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,473
+18.95%
|
-
|
|
Jun 11
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
3,870
-11.68%
|
$77,400
$20.59 P/Share
|
|
Jun 10
2024
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
3,870
-14.35%
|
$77,400
$20.32 P/Share
|
|
Jun 07
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
2,500
-7.02%
|
$50,000
$20.97 P/Share
|
|
Jun 07
2024
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+6.56%
|
$25,000
$10.41 P/Share
|
|
Jun 02
2024
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,087
-2.22%
|
$21,740
$20.75 P/Share
|
|
Jun 02
2024
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,314
-1.54%
|
$26,280
$20.75 P/Share
|
|
Jun 02
2024
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,746
-1.74%
|
$114,920
$20.75 P/Share
|
|
Jun 02
2024
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-1.97%
|
$38,380
$20.75 P/Share
|
|
Jun 02
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,462
-2.36%
|
$69,240
$20.75 P/Share
|
|
May 28
2024
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
1,539
-5.4%
|
$32,319
$21.0 P/Share
|
|
Apr 01
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.19%
|
$210,000
$21.65 P/Share
|
|
Apr 01
2024
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.82%
|
$130,000
$13.19 P/Share
|
|
Mar 15
2024
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,971
-1.78%
|
$125,391
$21.1 P/Share
|
|
Mar 15
2024
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,780
+3.39%
|
-
|
|
Mar 15
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,189
-1.47%
|
$45,969
$21.1 P/Share
|
|
Mar 15
2024
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,318
+2.82%
|
-
|
|
Mar 06
2024
|
Phillip G. Febbo Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,904
+30.01%
|
-
|